Learn how to leverage generative AI to support and improve your productivity at work. The next cohort will take place online on April 28 and 30, 2026, in French.
We use cookies to analyze the browsing and usage of our website and to personalize your experience. You can disable these technologies at any time, but this may limit certain functionalities of the site. Read our Privacy Policy for more information.
Setting cookies
You can enable and disable the types of cookies you wish to accept. However certain choices you make could affect the services offered on our sites (e.g. suggestions, personalised ads, etc.).
Essential cookies
These cookies are necessary for the operation of the site and cannot be deactivated. (Still active)
Analytics cookies
Do you accept the use of cookies to measure the audience of our sites?
Multimedia Player
Do you accept the use of cookies to display and allow you to watch the video content hosted by our partners (YouTube, etc.)?
Joshua Durso-finley
Alumni
Publications
Deep Learning Prediction of Response to Disease Modifying Therapy in Primary Progressive Multiple Sclerosis (P1-1.Virtual)
Disability progression in multiple sclerosis remains resistant to treatment. The absence of a suitable biomarker to allow for phase 2 clinic… (see more)al trials presents a high barrier for drug development. We propose to enable short proof-of-concept trials by increasing statistical power using a deep-learning predictive enrichment strategy. Specifically, a multi-headed multilayer perceptron is used to estimate the conditional average treatment effect (CATE) using baseline clinical and imaging features, and patients predicted to be most responsive are preferentially randomized into a trial. Leveraging data from six randomized clinical trials (
n
= 3,830), we first pre-trained the model on the subset of relapsing-remitting MS patients (
n
= 2,520), then fine-tuned it on a subset of primary progressive MS (PPMS) patients (
n
= 695). In a separate held-out test set of PPMS patients randomized to anti-CD20 antibodies or placebo (
n
= 297), the average treatment effect was larger for the 50% (HR, 0.492; 95% CI, 0.266-0.912;
p
= 0.0218) and 30% (HR, 0.361; 95% CI, 0.165-0.79;
p
= 0.008) predicted to be most responsive, compared to 0.743 (95% CI, 0.482-1.15;
p
= 0.179) for the entire group. The same model could also identify responders to laquinimod in another held-out test set of PPMS patients (
n
= 318). Finally, we show that using this model for predictive enrichment results in important increases in power.